Molina Healthcare cleared a deeply reset bar in the third quarter. Adjusted earnings of $0.89 per share beat the $0.72 consensus by 11.3% and topped the $0.80 Earnings Whisper number. Revenue of $11.082 billion exceeded the $10.93 billion estimate by 1.4%. Still, the beat came against a backdrop of steep contraction: earnings fell 51.6% year over year, revenue declined 3.4%, and adjusted EPS has now stepped down from $2.35 in the first quarter to $1.51 in the second and $0.89 in the third. That is the central tension. Management argues that Medicaid margins are near an inflection, yet the same call lowered the 2027 earnings bridge that investors use to value that recovery.
The quality of the beat deserves scrutiny. GAAP EPS was $0.73, and the consolidated medical care ratio rose to 92.9% from 92.6% a year ago. The deterioration sits squarely in Medicaid, where the MCR climbed to 93.0% from 92.0% and medical margin fell to $577 million from $639 million despite higher segment premiums. The mix improved elsewhere. Marketplace's MCR dropped to 92.5% from 95.6%, and Medicare improved to 93.0% from 93.6%, but Marketplace membership collapsed to 267,000 from 713,000. Total membership fell to 4.86 million from 5.63 million. Favorable prior-year reserve development reached $352 million through nine months, versus $124 million a year earlier, while days in claims payable slipped to 44 from 46. Those figures do not invalidate the quarter, but they suggest the cushion beneath reported margins is thinner than a year ago. The balance sheet is the cleaner story. Parent cash rose to roughly $608 million, up from about $290 million in June and $223 million at year-end, and nine-month operating cash flow was $629 million versus a $237 million outflow last year.
The call is where the setup shifted, and it cut both ways. On the constructive side, management raised its 2026 Medicaid rate outlook to 4.5% from 4.0%. Draft January 2027 rates average about 7% on 80% of the cohort, which represents about 55% of premium. The initial 2027 rate view of roughly 6% compares with an assumed trend of 5.5% to 6%. CEO Joseph Zubretsky said the company is "likely observing the beginning of the turn in Medicaid margins," and legacy Medicaid's underlying MCR is guided to improve 50 to 60 basis points sequentially in the fourth quarter, excluding Florida. However, the 2026 Medicaid cost trend was raised to 5.5% from 5.0%. Medicaid MCR guidance held at 92.9% only because rate gains absorbed that pressure. In other words, rates are catching up to costs rather than outrunning them.
The forward cuts give bears legitimate ammunition. Delays in the Georgia Medicaid and Texas STAR/CHIP implementations, now pushed to late 2027 or 2028, drove the 2027 premium outlook down to at least $45 billion. That compares with $46.5 billion last quarter and $48 billion at Investor Day. The embedded-earnings harvest for 2027 fell to $4.00 from about $4.50, and the preliminary 2027 EPS building blocks dropped to more than $9.50 from more than $10. Near term, the reaffirmed floor of at least $5.25 implies roughly $0.50 of fourth-quarter EPS. The Florida contract weighs on that figure. It launched smoothly with 115,000 members at a $6 billion run-rate but is expected to run near a 99% MLR. The release attributes $1.50 per share of full-year pressure to the Florida implementation, while the call framed the fourth-quarter drag at about $1. The Marketplace loss and the $1.00 drag from the exiting MAPD product add further pressure. Offsetting catalysts include benign early work-requirement data from Nebraska, six states building prospective acuity adjustments into rates, and about $26 billion of pending RFP bids. Management, however, still assumes roughly 6% Medicaid attrition in 2027.
Investors entered the report with modestly improving expectations. Earnings Whispers sentiment rose to 0.11 from 0.03, a mildly positive shift rather than a wholesale change in conviction. Shares, at $214.90, were 1.4% below the open following the July report, effectively flat for the quarter. They were also 16.7% above the 200-day moving average of $184.13, suggesting the market had already begun pricing a cyclical bottom. Price trend readings are neutral, while AVWAP remains positive.
The bottom line is that Molina delivered a credible beat and the most constructive rate commentary in several quarters. Still, it paired that optimism with a smaller 2027 premium base, a lower earnings bridge, and a higher cost trend. The margin turn looks increasingly plausible, but the size of the eventual earnings recovery just got smaller. With shares well above their long-term average, investors now need rate realization and execution on Florida to prove the recovery is real.